Biphenyl

Biphenyl

SCHEMBL659450

NC(=O)c1ccccc1.c1ccc(-c2ccccc2)cc1

nearest known ligand 0.84

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.84
TSHR P16473 2/20 0.84
POLB P06746 1/20 0.84
CYP3A4 P08684 1/20 0.84
PARP1 P09874 1/20 0.84
CYP2C19 P33261 1/20 0.84
RECQL P46063 1/20 0.84
BLM P54132 1/20 0.84
PMP22 Q01453 1/20 0.84
HSD17B10 Q99714 1/20 0.84
TDP1 Q9NUW8 1/20 0.84
L3MBTL1 Q9Y468 1/20 0.84
MKNK1 Q9BUB5 3/20 0.62
MKNK2 Q9HBH9 2/20 0.62
DHODH Q02127 2/20 0.61
PARP10 Q53GL7 2/20 0.56
PLA2G10 O15496 1/20 0.56
PLA2G2A P14555 1/20 0.56
KMO O15229 1/20 0.52
NPC1 O15118 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzamide SCHEMBL5070344 0.95 MAPT (0.76) MAPTTSHRPOLBCYP3A4PARP1
SCHEMBL153199 0.92 MKNK1 (0.71) MAPTTSHRPOLBCYP3A4PARP1
SCHEMBL27626919 0.92 MKNK1 (0.71) MAPTTSHRPOLBCYP3A4PARP1
Benzamide SCHEMBL1332331 0.92
Benzamide SCHEMBL30112947 0.92 PARP1 (1.00) MAPTTSHRPOLBCYP3A4PARP1
Benzamide SCHEMBL29618402 0.92
Benzamide SCHEMBL16352 0.92
Benzamide SCHEMBL6690447 0.92 PARP1 (1.00) MAPTTSHRPOLBCYP3A4PARP1
SCHEMBL21755166 0.92 PARP1 (1.00) MAPTTSHRPOLBCYP3A4PARP1
Benzamide SCHEMBL1222101 0.92 PARP1 (1.00) MAPTTSHRPOLBCYP3A4PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1480516-B1 MICROBICIDAL AGENTS ON THE BASIS OF BIPHENYL BENZAMIDE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2010-02-03 EP claimed
US-7186862-B2 Microbicidal agents on the basis of biphenylbenzamide derivatives BAYER CROPSCIENCE AG (DE) 2007-03-06 US claimed
US-20050119347-A1 Microbicidal agents on the basis of biphenyl benzamide derivatives BAYER INTELLECTUAL PROPERTY GMBH (DE) 2005-06-02 US claimed
CN-103980152-B Benzamide compounds with anti-tumor activity and its preparation method and application XI'AN JIAOTONG UNIVERSITY (CN) 2016-04-27 CN disclosed
US-9187523-B2 Substrate peptide sequences for plague plasminogen activator and uses thereof THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2015-11-17 US disclosed
EP-1896395-B1 MODIFIED MALONATE DERIVATIVES MERCK SHARP & DOHME (US) 2015-07-15 EP disclosed
CN-103980152-A Benzamide compound with antitumor activity as well as preparation method and application thereof UNIV XI AN JIAOTONG 2014-08-13 CN disclosed
US-20130131041-A1 SPIROCYCLIC COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2013-05-23 US disclosed
US-8349825-B2 Spirocyclic compounds MERCK SHARP & DOHME CORP. (US) 2013-01-08 US disclosed
US-8158825-B2 Modified malonate derivatives MERCK SHARP & DOHME CORP. (US) 2012-04-17 US disclosed
US-20120045474-A1 Substrate peptide sequences for plague plasminogen activator and uses thereof MOTIN VLADIMIR L (US) 2012-02-23 US disclosed
US-6258843-B1 DRUGS AS ENZYME INHIBITORS NOVARTIS AG (CH) 2001-07-10 US disclosed
US-6090817-A Phenylpyridine derivatives useful as phosphodiesterase inhibitors NOVARTIS AG (CH) 2000-07-18 US disclosed
US-6090817-A Phenylpyridine derivatives useful as phosphodiesterase inhibitors NOVARTIS AG (CH) 2000-07-18 US disclosed
CN-1216980-A Triaryl compounds NOVARTIS AG (CH) 1999-05-19 CN disclosed
CN-1216980-A Triaryl compounds NOVARTIS AG (CH) 1999-05-19 CN disclosed
EP-0885193-A1 TRIARYL COMPOUNDS Novartis AG (CH) 1998-12-23 EP disclosed
EP-0885193-A1 TRIARYL COMPOUNDS Novartis AG (CH) 1998-12-23 EP disclosed
WO-1997032853-A1 TRIARYL COMPOUNDS NOVARTIS AG (CH) 1997-09-12 WO disclosed
WO-1997032853-A1 TRIARYL COMPOUNDS NOVARTIS AG (CH) 1997-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119347-A1 Microbicidal agents on the basis of biphenyl benzamide derivatives DDT, MSR1, CYP1B1 MAPT 4798/4885TSHR 1824/4885POLB 1478/4885
US-20130131041-A1 SPIROCYCLIC COMPOUNDS BRDT, TXNRD3, HDAC1 MAPT 1986/4885TSHR 635/4885POLB 4013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.